Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a
period of 18 months has anti-inflammatory and neuroprotective properties in patients with
relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical
examination (EDSS and MSFC).